ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 72.5% in August

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 166,500 shares, a growth of 72.5% from the July 31st total of 96,500 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 62,600 shares, the days-to-cover ratio is currently 2.7 days.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABVX. BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They set a “buy” rating and a $43.00 price objective for the company. Laidlaw assumed coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a “buy” rating and a $48.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

ABIVAX Société Anonyme Trading Up 2.5 %

ABVX opened at $12.26 on Thursday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.23. The business’s 50-day moving average price is $12.28 and its 200-day moving average price is $13.50.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently bought and sold shares of the stock. Capstone Investment Advisors LLC raised its holdings in ABIVAX Société Anonyme by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after buying an additional 5,199 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme during the first quarter worth about $81,000. Kennedy Capital Management LLC grew its stake in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Ghisallo Capital Management LLC purchased a new position in ABIVAX Société Anonyme during the 4th quarter valued at about $642,000. Finally, Janus Henderson Group PLC raised its position in ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after purchasing an additional 131,414 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.